Building an ecosystem for advanced therapeutic modalities

Els Henckaerts Laboratory of Viral Cell Biology & Therapeutics KU Leuven



Focus on viral gene therapy

AAV gene therapy

At the forefront modern medicine

- Disease modification and curative treatment
- Single administration


AAV gene therapy: Current Landscape


- 149 unique clinical trials, 94 completed and 51 reached efficacy end point.
- Approved drug products (Luxturna[®] and Zolgensma[®])
- Zolgensma[®]: expected to generate global sales of \$2.5 billion by 2025
- Large investments in AAV GT within pharma (Novartis, Pfizer, Roche, etc)
- Market is projected CAGR of 25.71% (2022-2027)




AAV gene therapy's track record

Succes of clinical trials





Growing # of clinical trials



Kuzmin et al.Nature Reviews Drug Discovery, 2021

Maturing field with many players




AAV gene therapy: Challenges

2 deaths after Novartis' Zolgensma put gene therapy's liver safety in the spotlight once again

- **High doses** of vector required causing:
 - substantial off-target toxicity
 - serious adverse events
 - death in some clinical trials


 Robust, scalable and cost-effective manufacturing difficult to achieve




Another Astellas gene therapy hits a safety hurdle




The safety of Astellas' gene therapy portfolio has been thrust into the spotlight once again, after the FDA placed a clinical hold on a trial of its Pompe disease candidate AT845. Our vision: smart gene therapy development requires an integrated approach involving academic & clinical partners, biotech and pharma




Our strategy: KU Leuven is building an ecosystem that supports end-to-end AAV gene therapy development




Building towards a Gene Therapy Center of Excellence



Our AAV manufacturing capabilities



Bio-Incubator IV 600m²



Viral Cell **Biology Team**







Benjamien Moeyaert Research manager

Therapeutics Team



Nathalie Smeets PhD student





Caroline Dierickx

PhD student

Joeri Auwerx



Elien Costermans Lab technician USP



Inge Van Hove Program manager



Sofie De Munter Vector engineer



Marlies Leysen PhD student



Filip de Vin Vector engineer



Kirsten Welkenhuyzen Lab technician DSP



Sofie Molenberghs



Petrus Van der Auwera postdoc



Ingrid Pintens Finan admin & PA Els



Kristel Vuerinckx Lab technician assay dev



Teresa Torre Muruzabal Lab technician in vivo Senior scientist preclinical



Sophie Torrekens Lab manager



Irina Thiry Lab manager



Marwan Benaissa Lab technician



Tine Brouns USP engineer



Icham Lahbib Lab technician



Veronick Benoy Research manager



Samir Neisebeh Teaching fellow

